An international 3 year clinical study on the daily use of PHYTOSOYA® measured the effects on the endometrium (the internal lining of the uterus) and the breast.

The 305 women taking part in this clinical study had the following profile:
    - aged between 45 and 65 years old,
    - menopausal for at least two years,
    - suffering from hot flushes.

The study consisted of evaluating the daily dosage of 70 mg of isoflavones provided by PHYTOSOYA® for 3 years.

STUDY ON THE ENDOMETRIUM

After 3 years of use, no increase in the thickness of the endometrium was observed.
These results suggest that the specific PHYTOSOYA® extract, providing a daily quantity of 70 mg of isoflavones, does not stimulate the endometrium.
PHYTOSOYA® presents the special characteristic of containing a soya extract rich in daidzein, for which the SAFETY of the endometrium has been clinically proven according to a methodology that concurs with the recommendations of European authorities.


STUDY ON THE BREAST

The results demonstrate that after 3 years of use of PHYTOSOYA®, no change in mammary density was observed.
These results suggest that the specific PHYTOSOYA® extract, providing a daily quantity of 70 mg of isoflavones, does not have any effect on the BREAST.
PHYTOSOYA® presents the special characteristic of containing a soya extract rich in daidzein, the SAFETY of which on the BREAST is clinically proven.

« The studies cited above may not be extrapolated to other soya extracts with different daidzein and genistine compositions.
The extract contained in the PHYTOSOYA® range was specifically developed and studied with Laboratoires Arkopharma in order to guarantee its EFFECTIVENESS and SAFETY, for your WELLBEING. PHYTOSOYA® OUR ADVICE FOR OPTIMAL EFFECTIVENESS »